Mylan completes acquisition of generics business of Merck KGaA

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer said, "The new Mylan now has all of the critical attributes we need to ensure future success and deliver powerful growth. We have enhanced scale and stability, a truly global reach, vertical and horizontal integration, and breadth and depth in our management team. Most importantly, we have a common purpose and dedication to executing on our strategy and delivering superior shareholder returns."

The new Mylan is the third largest generic company worldwide, employs more than 11,000 people and has a global presence in more than 90 countries. Mylan's broad product offering now includes more than 570 products and the world's second largest portfolio of active pharmaceutical ingredients (APIs) with 126 U.S. drug master files (DMFs).